HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. HTG Molecular Diagnostics, Inc. is not a good value stock. HTG Molecular Diagnostics, Inc. is not very popular among insiders. HTG Molecular Diagnostics, Inc. is a mediocre stock to choose.
Log in to see more information.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that faci...
HTGM Fundamental Data by TradingView

News

Why Are HTG Molecular Diagnostics Shares Plunging Today
Why Are HTG Molecular Diagnostics Shares Plunging Today

Benzinga HTG Molecular Diagnostics (NASDAQ: HTGM) stock is down on Tuesday after the company announced a Chapter 11 bankruptcy filing.\n more…

HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention
HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention

Globe Newswire TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 ...\n more…

HTG Highlights the Advantages of Its Drug Discovery Engine
HTG Highlights the Advantages of Its Drug Discovery Engine

Globe Newswire TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-...\n more…

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights
HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights

Globe Newswire TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March31, 2023 and provided recent drug discovery business highlights. HTG has ...\n more…

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -25% and 1%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?\n\n KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.05 per share versus the Zacks ...\n more…

HTG Provides Update on Drug Discovery Partnering Initiative
HTG Provides Update on Drug Discovery Partnering Initiative

Globe Newswire TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit. HTG has pioneered a proprietary platform-...\n more…